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Abstract Multiple sclerosis (MS) with onset in childhood
offers a unique opportunity to study the infectious back-
ground of this disease but the immune reactions against
infectious agents in such children have only recently been
investigated. These and other epidemiological studies
strongly implicate involvement of one or more infectious
agents in the aetiology of MS, with Epstein-Barr virus
(EBV) being the prime candidate. Rather than being the
actual cause of MS, it is more probable that these agents
are involved in the development of immunoregulatory
pathways. These pathways, if disturbed by hygiene-related
factors including an altered sequence of infections, may
generate and maintain a deﬁcit within the immunological
network that facilitates, to particular early events in the
development of MS, preceding the onset of MS disease by
years or a decade. A framework that can serve as a guide
for further epidemiological, immunologic and molecular
biologic investigations is formulated. This approach may
shed light on the complex natural history of MS and may
lead to rational preventive and therapeutic strategies. It is
possible that, in the future, MS could be prevented by
vaccination against EBV in early childhood; the framework
is of relevance to the design of an appropriate type of
vaccine.
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Introduction
The pathogenesis of multiple sclerosis (MS) is certainly
complex and heterogeneous in nature [1], involving an
interplay between innate and environmental factors [2–4]
and genetic factors, notably the polymorphism of HLA [5].
The epidemiology of this disease strongly indicates that it
has emerged as a major neurological disorder in industri-
ally developed nations over the last 150 years and is likely
to be affected by hygiene-related factors [3, 6].
According to the so-called hygiene hypothesis [7],
modern living conditions in the industrialised nations iso-
late infants and children from many infectious challenges
that are required for the development of appropriate
immunoregulatory networks. This hypothesis has been
advanced to explain the rise in incidence of disease asso-
ciated with immune dysregulation, including asthma,
allergy, autoimmunity and at least some forms of cancer, in
the industrially developed world [7]. In addition, the
hypothesis suggests strategies for interventions for
the prevention of such diseases, as illustrated by studies on
the epidemiology of malignant melanoma which indicate
that certain vaccinations, BCG, vaccinia and yellow fever,
can substitute for the signiﬁcant protective effect of natural
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MS strongly indicate that this disease is likewise affected
by hygiene-related factors and by a history of infections
[3, 6], the challenge is to determine whether there is an
underlying distortion of immune responses in this complex
disease that could be prevented or corrected by therapeutic
intervention.
Associations of common infectious agents with MS
Evidence from epidemiological studies of a role for any of
the many common infections in the aetiology of MS is
largely inconsistent [3, 6]. This could be due to the pro-
longed silent stage of the disease, but recent studies on MS
commencing in childhood might be able to shed light on
this issue [6, 12–14]. Although there is no convincing
evidence that any speciﬁc active infection directly causes
MS, at least 14 speciﬁed infections have demonstrable
associations with this disease on the basis of serological
characteristics [2, 3, 6, 12–15], with Epstein-Barr virus
(EBV) emerging as the most likely single candidate for a
leading aetiological role [12–22]. This infection is unique
in that the prevalence of speciﬁc antibody is consistently
higher in children with MS as compared with healthy age-
matched controls [12–14], whereas at the typical age of
onset of MS (late 20s to early 30s) nearly all patients and
control subjects have already experienced EBV infection.
The two key points to emerge from these studies in relation
to EBV are that all children with MS had already been
infected with EBV [12–14], and that the levels of antibody
against the EBV EBNA1 antigen were very signiﬁcantly
higher in both adults and children with MS as compared
with controls [13, 14, 16, 23–25]. In this context, infections
with EBV usually occur in infancy in the developing
nations where MS is rare while in the industrialised nations
infection usually occurs later in life, often being delayed
until adolescence or early adulthood.
At the time of diagnosis of MS in children, the earlier
EBV infection had become latent and there was no sero-
logical sign of reactivation (IgM or anti-early antigen titres
C80 as measured in an indirect immuno ﬂuorescent assay)
[12, 13]. Moreover, in adult patients, the MS-associated
serological EBV pattern was probably established many
years before the onset of clinically evident MS as prior
infectious mononucleosis is a strong risk factor for MS
manifesting 2–20 years (mean around 10–12 years) later
[18, 25]. Taken together, these studies strongly indicate that
latent EBV infection is an essential predisposing condition
for the development of MS but other genetic, environmental
and hygiene-related conditions appear necessary for the
actual expression of the disease and the unifying condition
might be a dysregulated immune response.
A distinct possibility is that other infections synergise
with EBV in the aetiology of the disease and the timing of
infections might be important. In this context, Chlamydia
pneumoniae (CP) infection may play a special role [26], as
in a recent study on children with MS, CP-speciﬁc IgM
antibody points to a high frequency of fresh, recent or
reactivated infection with this pathogen at the onset of the
disease [12]. A ﬁnal key point is the demonstration that
slight, though statistically signiﬁcant, elevated levels of
antibody to certain common infectious agents other than
EBV and CP occur in children and adults with MS com-
pared with age matched control subjects [12, 15, 27]. This
ﬁnding does not, however, imply a direct causative relation
of any infection to MS as it could reﬂect a more general
dysregulation of immune function as a cause or conse-
quence of the development of the disease. It is indeed
likely that the elevated antibody concentrations have no
signiﬁcance per se for the development of MS but reﬂect a
shift in patterns of immune reactivity away from a pro-
tection and towards enhancement of the risk of disease.
Nevertheless, studies on these MS-associated infectious
agents could lead to the identiﬁcation of speciﬁc antigenic
determinants involved in the generation and maintenance
of immune dysregulation.
A hypothesis which relates MS to the ‘biography’
of the immune system
On the basis of the available epidemiological evidence it
may be postulated that MS is dependent on an infection
with EBV which, owing to hygiene-related factors, occurs
later than usual in life. Under such circumstances, the EBV
infection might encounter patterns of immune responsive-
ness generated by prior infections with certain other micro-
organisms. In this paper we suggest a scenario in which the
sequence of certain common infections results in immune
dysregulation favouring the onset of MS and in the fol-
lowing sections this hypothesis is elaborated.
The ‘biography hypothesis’ and regulatory T-cells
Recent studies have shown that the immune system con-
tains a very complex network of regulatory pathways. To
some extent these pathways are genetically determined, but
there is growing evidence that they are critically deter-
mined by the nature and timing of infections and other
immune challenges that an individual experiences earlier in
life. This could be termed the ‘biography’ of the immune
system.
The immunoregulatory pathways are based on popula-
tions of lymphocytes, termed regulatory T cells (Tregs), in
J Neurol (2009) 256:1052–1060 1053
123which there is currently considerable interest. In the case of
infectious disease, such populations may lead to rapid
resolution, the establishment of latent or persistent infec-
tion or to tissue damage by autoimmune processes [28].
Accordingly, Tregs have been termed ‘a dangerous neces-
sity’ [29]. This term implies that Tregs are neither ‘good’ or
‘bad’ per se but may, according to the overall pattern of
responsiveness, participate in appropriate immune reac-
tions leading to resolution of disease or in inappropriate
ones resulting in immunopathology.
The temporal sequence of infections, especially initial
and early ones, is crucial to the development of patterns of
immune reactivity as prior contacts with other antigens
may have induced cross-reactive T-helper cells competing
with Tregs. As a consequence Tregs normally induced by the
second pathogen may be marginalized or even eclipsed.
The latter phenomenon, also known as lateral inhibition,
has many parallels in biology, particularly in neurology.
The locking of an immune response into an eclipsed state
seems to involve an active deletion of clones of T-cells
occurring as a result of reinfections or reactivations [28]. In
the case of MS, infections such as those with HHV-6 [30,
31] and, possibly, with CP [12, 26] occurring before or at
the time of initial or reactivated EBV infection could have
such an effect.
Thus these prior contacts could have induced popula-
tions of Tregs that have a crucial role in protection against
MS but also cross-react with an epitope on EBV. A sub-
sequent infection by EBV could therefore generate a
dominant population of cross-reactive T-helper-cells which
could suppress or delete the Tregs.
Under normal physiological conditions, these Tregs could
either suppress other populations of T-cells which would
otherwise be able to induce autoimmune processes, includ-
ing those involved in the pathogenesis of MS, or they could
causetheexpansionofapopulationofspeciﬁcCD8
?T-cells
which would have an immune repair function. The nature of
the epitope or epitopes involved in this postulated process
remains unknown but, by analogy with the parallel studies
on melanoma mentioned above [10, 11], it is suggested that
key host epitopes involved are coded for by certain human
endogenous retroviruses (HERVs) as activation of these has
been extensively documented in MS [32, 33].
Accordingly, a challenge in MS research is to delineate
patterns of MS-related immune responses [34, 35], and the
Tregs involved, that affect the risk of MS both beneﬁcially
and detrimentally and the likely targets of these responses.
The IgG-anti-EBNA1 antibody concentrations are par-
ticularly elevated in patients with MS [13, 14, 16, 18, 23–
25], and systematic studies on the T-helper cell epitopes in
the EBNA1 protein revealed that CD4
? T-cells from
healthy EBV carriers matched for MS-associated HLA-DR
alleles recognised several epitopes within the central region
of the C-terminal domain of this protein but not other EBV-
encoded proteins [36, 37]. In contrast, those from MS
patients recognised many more epitopes spread over the
entire domain [36]. Concomitantly, the number of memory
T-cells directed against this domain is increased about
tenfold in MS and have been shown to be T-helper 1 cell
precursors and polarised effector memory cells [36, 37],
containing a subfraction of regulatory T-cells (Tregs)
[38, 39]. Tregs were suppressed in MS [40], and high level
of CD8
? T-cell activation against EBV but not cytomega-
lovirus was demonstrated early in the course of MS [41].
A search for the possible origin of competing T-helper
cells was undertaken with the BLAST analytical program
[42, 43]. Sequence homologies were evident over the entire
expanded EBNA1 epitope with proteins from CP and
HHV-6 (Table 1). This possible involvement of HHV-6
and CP in T cell competition is supported by the obser-
vation that the targets of T- and B-cells which have been
found to be MS-associated by systematic studies [34, 35]
also have homologies in HHV-6 and CP (Table 2).
The central EBNA1 epitope marginalized in MS (amino
acids FENIAEGLRALLARSHVER) could well have dif-
ferent functions in health and in MS and is therefore a
major putative candidate for generation of Tregs which
control the relevant immune processes. A speciﬁc or
functional deﬁciency of Tregs in MS has only recently been
recognised, and the need for a large cohort of Tregs for the
resolution of experimental autoimmune encephalomyelitis
has been demonstrated [44]. For the purpose of studying
the potential infectious and immunological background of
MS, it is relevant to search for homologies to this ‘epitope
No. 1’ in the MS-associated pathogens [42, 43]. Interest-
ingly, homologies to the putative epitope were found in all
these pathogens (Table 3).
Epitopes shared by various pathogens
and by a HERV peptide
It is likely that a diverse range of MS-associated infectious
agents other than EBV and, possibly, CP, is involved in the
generation and maintainance of the postulated immune
responses associated, beneﬁcially or detrimentally, with
MS. By generating populations of Tregs or of competing
T-helper cells, such infectious agents would play a role in
the generation of various immunological networks based
on Tregs which, in turn, would facilitate the expansion or
suppression of populations of effector T cells including
epitope-speciﬁc CD8
? T-cells. The epitope recognised by
these T-cells should be common to the MS-associated
infectious pathogens and to one or more cellular gene
products. The latter was preferentially sought in HERVs
since patients with MS expressed HERV-W env at higher
1054 J Neurol (2009) 256:1052–1060
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[32, 45] and a HERV-K18 env genotype was described as a
risk factor for MS [46].
A putative target epitope for effector T-cells in the
processes suggested above (‘epitope No. 2’) was identiﬁed
in a short peptide from the HERV-W env gene complex:
MPVPSAPST. It is predicted that this peptide is presented,
though only subdominantly, by diverse HLA class I mol-
ecules including Ld, A*0201, B*0702, B*5101, as
determined by reference to the SYFPEIHI database for
MHC ligands and peptide motifs [47].
Only three pathogens bearing the two homologies on the
same protein, which is postulated to be optimal for a
co-operation of the corresponding T-cells, have been
identiﬁed, namely, herpes simplex (1 and 2) virus (tegument
protein), measles (nucleoprotein), and varicella (tegument).
The MS-association of the serology of these pathogens
(higher speciﬁc antibody concentration) [16] was conﬁrmed
in a recent study: herpes simplex-2, P\0.0001; measles,
P\0.0001 and varicella, P\0.0001 [12]. The epidemi-
ological evidence for the MS-association of the majority of
the other pathogens in Table 3 is only weak and inconsis-
tent. Moreover, a simultaneous occurrence of homologies to
epitopes 1 and 2 was also found in a diverse range of
pathogens causing respiratory and gastrointestinal infec-
tions and which have also been associated, beneﬁcially and
Table 1 Homologies in proteins of HHV-6 and Chlamydia pneumoniae (CP) to the in MS expanded T-helper cell epitope in Epstein-Barr virus
EBNA1 (amino acids 400–478)
Speciﬁc T-cells directed against this region were found to be expanded in MS patients as compared to control individuals [36]; the region with
homologies in HHV-6 and CP proteins extends to EBNA1 amino acid position 640
* for identical amino acid; ?=conserved amino acid exchange; / = missing amino acid; arabic numbers for additional amino acids:
1 = DKK; 2 = PF; 3 = D
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unknown parasitic infections have recently been found to be
associated with a reduced risk of MS [51], and some para-
sitic organisms share the two homologies (Table 3,
footnote). In addition, preliminary studies indicate that
parasite infections in MS patients lead to fewer exacerba-
tions and this has been linked to the emergenceof Tregs[ 52].
The relatively widespread occurrence of these two homol-
ogies explains, at least in part, why the infectious
background of MS has proved so complex and difﬁcult to
deﬁne.
The MPVPSAPST-peptide is the amino-terminal part of
a small hypothetical protein of 29 amino acids encoded by
the complementary DNA strand of the HERV-WE1 env
gene which is conserved in all homologous HERV-W
sequences in the human genome. Gene transcripts of 21 of
25 open reading frames with an initiating start codon have
been found in association with MS according to genetic
data bank entries. Moreover, several other HERVs (-H, -K,
-L) exhibit this homology. As these HERV peptides are all
self-antigens, they could serve as targets, but not as
inducers, of the postulated MS-protective immune
response. The main HLA class I molecule A*0201 for the
presentation of the peptide, with a frequency of about 30%
in a European population, was shown to be associated with
a signiﬁcantly reduced MS risk (OR = 0.52, P = 0.0015)
[53].
A view on early events in the natural history of MS
Immune dysregulation in MS is likely to be an early
event [18, 22, 25, 41] preceding the onset of MS disease
by many years or a decade [18, 22, 25]. It should thus
be emphasized that the epidemiologic observations on
the possible infectious background of MS partly, if not
predominantly, reﬂect the earliest stage in the natural
history of MS. A situation similar to that postulated here
has been described in malignant melanoma in which, as
discussed above, cross-reactive protective immune
responses are induced by homologous epitopes in BCG,
vaccinia and yellow fever vaccines given at least
10 years before the onset of disease [8–11]. It was
suggested that melanocytes in the early stages of
malignant transformation, may be eliminated or repaired
by CD8
? T-cells which recognise cells expressing a
HERV peptide. This immune reaction seems to suppress
the genetic activity of HERV proviruses (env genes)
associated with malignant transformation [10, 54, 55].
The HERV env proteins probably impair the redox
Table 2 Homologies in proteins of sero-epidemiologic MS-associated pathogens to MS associated EBV-epitopes [34, 35]
Targets of higher frequent B- and T-cells in MS-patients as present in proteins of Epstein-Barr virus and consensus in proteins of other MS-
associated pathogens
Enhanced immune reactivity in MS patients in comparison with healthy control subjects as identiﬁed by systematic studies [34, 35]; consensus in
other proteins to the EBV sequence given by * for identical amino acid, ? for similar amino acid (conservative exchange), and / for missing
amino acid; one additional homology in vaccinia virus
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thione peroxidase [10]. In MS there is still another
environmental risk factor, namely, suboptimal levels of
bio-active vitamin D [4], which, as demonstrated in rat
astrocytes, may impair via c-glutamyl transpeptidase
intra-cellular glutathione levels [56].
Table 3 MS-associated pathogens and homologies in proteins thereof to candidate epitopes No. 1 (EBV EBNA1, putative Treg) and No. 2
(HERV-W)
* for identical amino acid; ?=conserved amino acid exchange; / = missing amino acid; arabic numbers for additional amino acids: 1 = TEE;
2 = AG; 3 = QKE; 4 = YCK; 5 = AT; 6 = V; 7 = V; 8 = LAT
Pathogens against which higher antibody concentrations were observed as compared with control individuals. Homologies to both epitopes were
also found in the following pathogens causing respiratory and gastrointestinal diseases: Bordetella parapertussis, Corynebacterium diphtheriae,
cytomegalo virus, Haemophilus inﬂuenzae, human corona virus, human rota virus, Mycobacterium tuberculosis (also M. bovis, strain BCG),
Salmonella enterica, Pseudomonas aeruginosa, Serratia marcescens, A and in two parasites causing gastrointestinal infections: Entamoeba
histolytica, Giardia lamblia
Proteins with homologies to epitope 1/epitope 2, respectively: adeno virus: DNA stabilization protein/protein V; Chlamydia pneumoniae:
hypothetical protein cpB U609/hypothetical protein; Epstein-Barr virus: EBNA1/BBLF2/BBLF3; herpes simplex-1: tegument/tegument; herpes
simplex-2: tegument/tegument; HHV-6: tegument/major capsid; measles virus: nucleoprotein/nucleoprotein; Mycoplasma pneumoniae: phos-
phate import ATP-binding protein pstB/enolase; parainﬂuenza-2: large protein/nucleocapsid; RSV: fusion protein precursor/glycoprotein;
rubella: RNA-directed RNA polymerase/E1; vaccinia: 14K membrane protein/putative DNA-binding core; varicella virus: tegument/tegument
J Neurol (2009) 256:1052–1060 1057
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series, such as LM1, were identiﬁed as possible relevant
mediators as they suppress HERV genes [10] and induce
lytic replication cycles in cells latently infected with EBV
[57, 58], thereby releasing a viral antigen which would be
readily recognisable by the speciﬁc immune system. The
failure of such protective mechanisms would facilitate an
uncontrolled establishment of the observed extensive EBV
infection of brain lymphatic tissue in MS, albeit only at a
low level of virus activity [59–62]. The speciﬁcity of
the process for the brain may be associated with the
high content of gangliosides in nervous tissue, as other
gangliosides may antagonize the activity of those that
possibly protect against MS.
Multiple sclerosis is certainly a complex disease entity
and the pathogenic process involves more than just
increased neuro-degeneration. In particular, reduced re-
myelination contributes to disease progression. Thus,
relevant targets in addition to the HERV peptide might
exist, possibly host proteins with a homology to the HERV
peptide. One such candidate is neuron-speciﬁc ankyrin-2
which, owing to complementary binding sites, forms a
complex with spectrin. In an animal model of remyelina-
tion of axons the latter is the target of an immune repair
mechanism mediated by a monoclonal antibody [63].
Conclusion
Based on epidemiological considerations, it is postulated
that the relatively high risk of MS in the industrialised
nations is due to hygiene-related changes in the sequence
of common infections, resulting in the emergence of pat-
terns of immune reactivity that either cause, or fail to
protect against, the development of MS. Further epidemi-
ological studies are required to determine whether the
timing of EBV infection is related to the risk of MS [20].
Based on studies of altered immune responses to certain
infectious agents and evidence for the expression of
HERVs in MS, epitopes that have a putative role,
depending on the appropriate or inappropriate activity of
immunoregulatory networks, in protection against or pre-
disposition to MS have been delineated.
Studies based on the above considerations should focus
on processes that initiate MS years or a decade before
manifestation of the disease. Subsequently, a better
understanding of the highly complex immunopathology of
MS will, hopefully, lead to the eventual development of
vaccination strategies for the prevention or correction of
anomalies in immune function. Such vaccines could well
work by preventing or correcting hygiene-related immune
dysregulation [64]. It has previously been postulated that a
vaccine based on EBV should afford a high level of
protection against MS [16], but the exact nature of an
efﬁcient and safe vaccine would depend on the nature of
the relationship between EBV and MS. If the framework
presented in this study is in principle conﬁrmed, the
appropriate vaccine is most likely to be a living attenuated
one that induces a strong T cell response to EBV epitopes
but is not expressing EBV EBNA1 in latency.
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